Total : 1 View more »
Pathumwan, Bangkok Thailand
Child and Babycare Products, Healthcare Preparations or Products, Healthcare or Screening Services, Baby Foods, Health Supplements...
TEL: 662-2679048-51
FAX: 662-2679043
Total : 26 View more »
Analysts are looking for EPS of 90c on revenue of $7.76B. The consensus range is 88c-91c for EPS, and $7.45B-$8.15B for revenue, according to First Call.
http://seekingalpha.com/article/166281-earnings-preview-abbott-labs?source=yahoo
SAN FRANCISCO (MarketWatch) -- Abbott Laboratories said late Wednesday that it agreed to buy optical device maker Visiogen Inc. for $400 million in cash. The acquisition of privately-held Visiogen will expand Abbott's vision care portfolio into next-generation intraocular lenses, or devices used to
WASHINGTON (AP) -- Drug and medical-device company Abbott Laboratories is scheduled to report earnings for the third quarter on Wednesday. The following is a summary of
http://finance.yahoo.com/news/Earnings-Preview-Abbott-apf-988328403.html?x=0&.v=3
Abbott to Develop New Heart Failure Test on ARCHITECT® Immunochemistry Diagnostics Platform
http://www.abbott.com/global/url/pressRelease/en_US/60.5:5/Press_Release_0796.htm?referrer=RSS
Total : 45 View more »
Nov 12, 2009 (SmarTrend(R) News Watch via COMTEX) --
11/12/2009 - Abbott Laboratories (NYSE:ABT) announced today an agreement to acquire the global rights to PanGenetics BV's PG110 fully humanized antibody to Nerve Growth Factor. PG110 is a novel biologic that targets NGF for the treatment of chronic pain in Phase I clinical trial development. Under the terms of the agreement, Abbott will pay $170 million upfront plus additional milestone payments, for a total of up to $190 million. The agreement is subject to customary closing conditions and regulatory approvals and is expected to close in Q4. Senior vice president of global research and development for Abbott John Leonard, M.D., said, "The goal for treatment of chronic pain continues to be potent, long-lasting analgesia that is tolerable for patients without the potential for dependence and abuse. NGF blockers have demonstrated the potential to address all of these needs, making them a promising treatment for chronic pain patients."
Write to Chip Brian at cbrian@tradethetrend.com
---------------------------------------------------------------------------------------------
SmarTrend analyzes over 5,000 securities simultaneously throughout the trading day and provides its subscribers with trend change alerts in real time. To get a free trial of our trading calls and maximize your trading results, please visit http://www.TradeTheTrend.com.
Get exclusive, actionable insight into how the market is expected to trend prior to market open with our free morning newsletter. Sign up at: http://www.TradeTheTrend.com/signup.html
Tags: acquisition clinical market nyse president research and development securities trial
Companies: Abbott Laboratories (ABT)
Nov 11, 2009 (SmarTrend(R) Spotlight via COMTEX) --
Abbott Laboratories (NYSE:ABT) is trading 1% higher (up $0.52 to $53.32) today on volume of 3,035,328 shares. The stock is trading near its 52-week high of $57.39. We are watching for a close above that level.
Abbott Laboratories is currently above its 50-day moving average of $49.00 and above its 200-day moving average of $47.23.
SmarTrend is bullish on shares of ABT and our subscribers received an Uptrend alert on May 12, 2009 at $45.38, which has returned 17.5% to date.
Write to Chip Brian at cbrian@tradethetrend.com
---------------------------------------------------------------------------------------------
SmarTrend analyzes over 5,000 securities simultaneously throughout the trading day and provides its subscribers with trend change alerts in real time. To get a free trial of our trading calls and maximize your trading results, please visit http://www.TradeTheTrend.com.
Get exclusive, actionable insight into how the market is expected to trend prior to market open with our free morning newsletter. Sign up at: http://www.TradeTheTrend.com/signup.html
Tags: market nyse securities
Companies: Abbott Laboratories (ABT)
Nov 13, 2009 (Datamonitor Financial Deals Tracker via COMTEX) --
PanGenetics B.V., a Netherlands-based antibody development company, has entered into an agreement with Abbott Laboratories, under which Abbott will acquire the global rights to a nerve growth factor humanized antibody, PG110. Abbott is a US-based company engaged in the discovery, development, manufacturing, and sale of pharmaceutical and nutritional products.
PG110 is currently in a phase I clinical trial in patients with osteoarthritis and represents a promising new therapeutic for the treatment of chronic pain.
The agreement includes an upfront payment of $170 million plus additional milestone payments, for a total of up to $190 million.
J. P. Morgan is acting as a financial advisor to PanGenetics.
Deal Type Partnership Sub-Category Licensing Agreement Deal Status Announced: 2009-11-12
Deal Participants
Partner 1 (Company) Abbott Laboratories Partner 2 (Company) PanGenetics B.V.
Tags: acquisition clinical manufacturing netherlands partnership pharmaceuticals products trial
Companies: Abbott Laboratories (ABT)
Nov 12, 2009 (Fresh Brewed Media via COMTEX) --
Abbott Laboratories (NYSE: ABT) opened at $53.39. So far today, the stock has hit a low of $53.01 and a high of $53.80. ABT is now trading at $53.23, down $0.04 (-0.08%). Over the last 52 weeks the stock has ranged from a low of $41.27 to a high of $57.39. Wedbush Morgan initiated ABT at Outperform this morning, giving the stock a $62 price target. Technical indicators for the stock are bullish and S&P gives ABT a positive 4 STARS (out of 5) buy ranking. If you are looking for a hedged play on ABT the stock seems like it could be a candidate for a February out-of-the-money bull-put credit spread below the 48 range.
ABR-Seven Summits Strategic Investments NewsBite Goto www.iotogo.com/18w1 for our free report titled, The 18 Ways To Know When It's Time To Dump A Stock
Companies: Abbott Laboratories (ABT)
Total : 323 View more »
News and project information on the Abbott Laboratories Biotech Facility, Barceloneta
http://www.pharmaceutical-technology.com/projects/puertorico/
Welcome To The Family: Abbott Medical Optics Joins Our Team The initials are the same, but the 3,600 employees of AMO, formerly Advanced Medical Optics, are now part of Abbott as the transaction to acquire this established global leader in vision care has been completed.
The CLAVE Connector is an exclusive proprietary product manufactured by ICU Medical which is available through Abbott Laboratories and independent international specialty distributors.
Gent (Belgium) – July 12, 2002 - Innogenetics announced today a new distribution arrangement, whereby the Innogenetics’ LiPA HLA tissue typing products will be marketed worldwide by both Innogenetics and Abbott Laboratories.
http://www.innogenetics.com/site/pressview.asp?id=101&lang=E
powered by 
Total : 7,690,000 View more »
Discovers, develops, manufactures and sells pharmaceutical and nutritional products such as drug delivery systems, antibiotics and prepared infant formulas. Includes investor an ...
Abbott Laboratories (NYSE: ABT) is a diversified pharmaceuticals health care company. It has 72,000 employees and operates in over 130 countries. [1]
Unless otherwise specified, all product names appearing in this Internet site are trademarks owned by or licensed to Abbott Laboratories, its subsidiaries or affiliates.
http://www.abbott.com/global/url/content/en_US/50:50/general_content/General_Content_00013.htm
Abbott Laboratories pharmaceutical products division involves innovative pharmaceuticals which touch many lives each day. Treatments for rheumatoid arthritis, HIV/AIDS, acid reflux ...
Navigation [accesskey 1] Content [accesskey 2] Site Search [accesskey 3] Job Seekers Login [accesskey 4] top of page [accesskey 5] PharmiWeb.com, From PharmiWeb Solutions PharmiWeb.com from PharmiWeb Solutions PharmiWeb.com Home Page 19 June 2008 Select a company 1st Pharma People 20:20 Selection
http://www.pharmiweb.com/events/event.asp?eventId=4133&channel=2
Oncology RD is currently booming with pharmaceuticals on a quest to develop effective cancer drugs. The established standard of care – surgery, radiotherapy and chemotherapy is fast giving way to a high-tech array of targeted therapies.
http://www.pharmiweb.com/events/event.asp?eventId=4023§ion=howto